Abstract
Background Osteoarthritis (OA) is a common degenerative disease affecting people and animals, resulting in persistent pain and joint deformities. Its growing prevalence presents considerable difficulties to public health and veterinary care systems worldwide. Despite substantial research, the molecular pathways underlying OA pathogenesis remain poorly understood, limiting the development of effective treatment strategies. Exosomes, or small endosomal membrane microvesicles, have emerged as intriguing vehicles for intercellular communication and medicinal administration in a variety of illnesses, including OA. However, their efficacy and action methods in preclinical OA models require additional exploration.
Methods We analyzed several databases from 2016 to 2023 for original studies on exosome treatment in preclinical OA models. The inclusion criteria included studies that used exosomes generated from mesenchymal stem cells (MSCs) in both human and animal models of OA. Thematic synthesis and data extraction were used to examine research features, dosage administration techniques, and efficacy results. The quality of included studies was assessed using recognized criteria, and statistical analysis was performed to determine the efficacy of exosome treatment in decreasing Osteoarthritis Research Society International (OARSI) scores.
Results Our study comprised thirteen peer-reviewed articles that included both human and animal models of OA. Most trials used bone marrow MSC-derived exosomes administered intra-articularly. The analysis of OARSI scores revealed a considerable reduction in joint deterioration following exosome therapy. Source analysis demonstrated that exosome treatment originating from human and animal MSCs was consistently effective. However, an assessment of study quality revealed potential biases and limitations, emphasizing the need for more research to validate these findings and refine therapy options for OA management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
riya.mukherjee1896{at}gmail.com (R.M.), ramendra.pandey{at}gmail.com (R.P.P.), ramendra.pandey{at}ddn.upes.ac.in, cmchang{at}mail.cgu.edu.tw (C.M.C.), cmchang{at}mail.cgu.edu.tw (C.M.C.)
Data Availability
All data produced in the present work are contained in the manuscript
